• Krieg DeVault Recognized for Unparalleled Client Relationships
    in BTI Power Rankings.

    BTI 2017 BTI 2017
  • Krieg DeVault Attorneys named to Best Lawyers in America© Listing

    2017 Best Lawyers Slider 2017 Best Lawyers Slider
  • ERMCO ESOP ERMCO ESOP
PDFEmailPrint

Indiana Proposes New Rule Impacting Pharmacy Reimbursement

PDFEmailPrint

January 23, 2019

By: Stephanie T. Eckerle and Brandon W. Shirley

The Indiana Family and Social Services Administration (“FSSA”) published a proposed rule that affects Medicaid reimbursement for legend and non-legend drugs. A public hearing about this rule is schedule for January 31, 2019 at 10:00am EST, and the FSSA is accepting public comments through that date.

The most significant changes affect coverage of non-legend drugs, namely, that all Medicaid programs (fee-for-service and managed care) will only cover non-legend drugs on the over-the-counter formulary, and at a rate that is the lowest of the “state over-the-counter maximum allowable cost plus a professional dispensing fee” or the provider’s usual and customary charge, which term is defined in existing Medicaid rules. With respect to legend and non-legend drugs, FSSA proposes to reduce the professional dispensing fee to $10.48, and deletes “Health Maintenance Organization pharmacy services” from the list of services exempt from the copayment requirement. The proposed rule includes two program integrity  measures: 1) prohibiting split billing of legend and non-legend drugs to capture more dispensing fees; and 2) prohibiting a provider from “circumventing prior authorization criteria.”  The proposed rule does not define that term or specify whether the prohibition requires intent to violate such criteria.

Such changes may seem minor but can have a substantial business impact. Please contact Brandon W. Shirley at bshirley@kdlegal.com or Stephanie T. Eckerle at seckerle@kdlegal.com if you wish to submit a public comment or need assistance complying with applicable regulatory requirements.